Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G - PubMed (original) (raw)
Generation of mutated variants of the human form of the MHC class I-related receptor, FcRn, with increased affinity for mouse immunoglobulin G
Jinchun Zhou et al. J Mol Biol. 2003.
Abstract
Much data support the concept that the MHC class I-related receptor FcRn serves to regulate immunoglobulin G (IgG) concentrations in serum and other diverse body sites in both rodents and humans. Previous studies have indicated that the human ortholog of FcRn is endowed with unexpectedly high stringency in binding specificity for IgGs. In contrast to mouse FcRn, which binds promiscuously to IgGs across species, human FcRn does not bind to mouse IgG1 or IgG2a, and interacts weakly with mouse IgG2b. Here, we investigate the molecular basis for this high-level specificity. We have systematically mutated human FcRn residues to the corresponding mouse FcRn residues in the regions that encompass the FcRn-IgG interaction site. Notably, mutation of the poorly conserved residue Leu137 of human FcRn to glutamic acid (L137E) generates a human FcRn mutant that binds to mouse IgG1 and mouse IgG2a with equilibrium dissociation constants of 13.2 microM and 14.4 microM, respectively. From earlier high-resolution structural analyses of the rat FcRn-rat Fc complex, residue 137 of human FcRn is predicted to contact residue 436 of IgG, which can be either His436 (mouse IgG1, mouse IgG2a) or Tyr436 (human IgG1, mouse IgG2b). The simplest interpretation of our data for the L137E mutant is therefore that replacement of the Leu137-Tyr436 (human) by the Glu137-His436 (mouse) pair generates a receptor that can bind to mouse IgG1 and mouse IgG2a. The L137E mutation reduces the affinity of human FcRn for human IgG1 by about twofold, consistent with the introduction of a less favorable Glu137-Tyr436 interaction. However, the analysis of the effects of other mutations on the binding to different IgGs indicates that the contribution to binding of the interaction of FcRn residue 137 with IgG residue 436 can vary. This suggests the existence of distinct docking topologies that are accompanied by variations in contacts between these two residues for different FcRn-IgG pairs. Our observations are of direct relevance to understanding the molecular nature of the human FcRn-IgG interaction. In turn, understanding human FcRn function has significance for the optimization of the serum half-lives of therapeutic and prophylactic antibodies.
Similar articles
- Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis.
Zhou J, Mateos F, Ober RJ, Ward ES. Zhou J, et al. J Mol Biol. 2005 Feb 4;345(5):1071-81. doi: 10.1016/j.jmb.2004.11.014. Epub 2004 Dec 16. J Mol Biol. 2005. PMID: 15644205 - The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A. Abdiche YN, et al. MAbs. 2015;7(2):331-43. doi: 10.1080/19420862.2015.1008353. MAbs. 2015. PMID: 25658443 Free PMC article. - Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).
West AP Jr, Bjorkman PJ. West AP Jr, et al. Biochemistry. 2000 Aug 15;39(32):9698-708. doi: 10.1021/bi000749m. Biochemistry. 2000. PMID: 10933786 - Multiple roles for the major histocompatibility complex class I- related receptor FcRn.
Ghetie V, Ward ES. Ghetie V, et al. Annu Rev Immunol. 2000;18:739-66. doi: 10.1146/annurev.immunol.18.1.739. Annu Rev Immunol. 2000. PMID: 10837074 Review. - FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions.
Challa DK, Velmurugan R, Ober RJ, Sally Ward E. Challa DK, et al. Curr Top Microbiol Immunol. 2014;382:249-72. doi: 10.1007/978-3-319-07911-0_12. Curr Top Microbiol Immunol. 2014. PMID: 25116104 Review.
Cited by
- Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM, Avery LB, King AC, Kavosi M, Wang M, O'Hara DM, Tchistiakova L, Katragadda M. Piche-Nicholas NM, et al. MAbs. 2018 Jan;10(1):81-94. doi: 10.1080/19420862.2017.1389355. Epub 2017 Nov 3. MAbs. 2018. PMID: 28991504 Free PMC article. - Germline deletion of β2 microglobulin or CD1d reduces anti-phospholipid antibody, but increases autoantibodies against non-phospholipid antigens in the NZB/W F1 model of lupus.
Singh RR, Yang JQ, Kim PJ, Halder RC. Singh RR, et al. Arthritis Res Ther. 2013 Mar 27;15(2):R47. doi: 10.1186/ar4206. Arthritis Res Ther. 2013. PMID: 23531237 Free PMC article. - Targeting FcRn for the modulation of antibody dynamics.
Ward ES, Devanaboyina SC, Ober RJ. Ward ES, et al. Mol Immunol. 2015 Oct;67(2 Pt A):131-41. doi: 10.1016/j.molimm.2015.02.007. Epub 2015 Mar 9. Mol Immunol. 2015. PMID: 25766596 Free PMC article. Review. - Neonatal Fc receptor: from immunity to therapeutics.
Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, Blumberg RS. Kuo TT, et al. J Clin Immunol. 2010 Nov;30(6):777-89. doi: 10.1007/s10875-010-9468-4. Epub 2010 Oct 1. J Clin Immunol. 2010. PMID: 20886282 Free PMC article. Review. - Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM. Kenanova V, et al. Cancer Res. 2005 Jan 15;65(2):622-31. Cancer Res. 2005. PMID: 15695407 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials